Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Leif William Ellisen, M.D.,Ph.D.


The research activities and funding listed below are automatically derived from NIH ExPORTER and other sources, which might result in incorrect or missing items. Faculty can login to make corrections and additions.
  1. R01CA122589 (ELLISEN, LEIF W) Sep 24, 2007 - Mar 31, 2018
    Function and mechanism of REDD1/mTOR signaling in metabolism and tumorigenesis
    Role: Principal Investigator
  2. R01DE015945 (ELLISEN, LEIF W) Apr 1, 2004 - Jul 31, 2022
    P63 Mechanisms and mediators in HNSCC
    Role: Principal Investigator
  3. K08CA082831 (ELLISEN, LEIF W) Sep 29, 1999 - Aug 31, 2004
    Role: Principal Investigator

Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
  1. Wu B, Ellisen LW. Loss of p53 and genetic evolution in pancreatic cancer: Ordered chaos after the guardian is gone. Cancer Cell. 2022 Nov 14; 40(11):1276-1278. PMID: 36379206.
    Citations:    Fields:    Translation:Animals
  2. Lehman CD, Mercaldo S, Lamb LR, King TA, Ellisen LW, Specht M, Tamimi RM. Deep Learning vs Traditional Breast Cancer Risk Models to Support Risk-Based Mammography Screening. J Natl Cancer Inst. 2022 10 06; 114(10):1355-1363. PMID: 35876790; PMCID: PMC9552206.
    Citations:    Fields:    
  3. Spring LM, Han H, Liu MC, Hamilton E, Irie H, Santa-Maria CA, Reeves J, Pan P, Shan M, Tang Y, Graham JR, Hazard S, Ellisen LW, Isakoff SJ. Author Correction: Neoadjuvant study of niraparib in patients with HER2-negative, BRCA-mutated, resectable breast cancer. Nat Cancer. 2022 Sep; 3(9):1138. PMID: 35931884; PMCID: PMC9499859.
  4. Denault E, Nakajima E, Naranbhai V, Hutchinson JA, Mortensen L, Neihoff E, Barabell C, Comander A, Juric D, Kuter I, Mulvey T, Peppercorn J, Rosenstock AS, Shin J, Vidula N, Wander SA, Moy B, Ellisen LW, Isakoff SJ, Iafrate AJ, Gainor JF, Bardia A, Spring LM. Immunogenicity of SARS-CoV-2 vaccines in patients with breast cancer. Ther Adv Med Oncol. 2022; 14:17588359221119370. PMID: 36051470; PMCID: PMC9425892.
  5. Spring LM, Han H, Liu MC, Hamilton E, Irie H, Santa-Maria CA, Reeves J, Pan P, Shan M, Tang Y, Graham JR, Hazard S, Ellisen LW, Isakoff SJ. Neoadjuvant study of niraparib in patients with HER2-negative, BRCA-mutated, resectable breast cancer. Nat Cancer. 2022 08; 3(8):927-931. PMID: 35788722; PMCID: PMC9402431.
  6. Koh SB, Ellisen LW. Immune activation and evolution through chemotherapy plus checkpoint blockade in triple-negative breast cancer. Cancer Cell. 2021 12 13; 39(12):1562-1564. PMID: 34767761.
    Citations: 2     Fields:    Translation:Humans
  7. Koh SB, Dontchos BN, Bossuyt V, Edmonds C, Cristea S, Melkonjan N, Mortensen L, Ma A, Beyerlin K, Denault E, Niehoff E, Hirz T, Sykes DB, Michor F, Specht M, Lehman C, Ellisen LW, Spring LM. Systematic tissue collection during clinical breast biopsy is feasible, safe and enables high-content translational analyses. NPJ Precis Oncol. 2021 Sep 21; 5(1):85. PMID: 34548623.
  8. Xu J, Keenan TE, Overmoyer B, Tung NM, Gelman RS, Habin K, Garber JE, Ellisen LW, Winer EP, Goss PE, Yeap BY, Chabner BA, Isakoff SJ. Phase II trial of veliparib and temozolomide in metastatic breast cancer patients with and without BRCA1/2 mutations. Breast Cancer Res Treat. 2021 Oct; 189(3):641-651. PMID: 34417675.
    Citations: 1     Fields:    Translation:HumansCTClinical Trials
  9. Coates JT, Sun S, Leshchiner I, Thimmiah N, Martin EE, McLoughlin D, Danysh BP, Slowik K, Jacobs RA, Rhrissorrakrai K, Utro F, Levovitz C, Denault E, Walmsley CS, Kambadakone A, Stone JR, Isakoff SJ, Parida L, Juric D, Getz G, Bardia A, Ellisen LW. Parallel Genomic Alterations of Antigen and Payload Targets Mediate Polyclonal Acquired Clinical Resistance to Sacituzumab Govitecan in Triple-Negative Breast Cancer. Cancer Discov. 2021 10; 11(10):2436-2445. PMID: 34404686; PMCID: PMC8495771.
    Citations: 4     Fields:    Translation:HumansCells
  10. Mortensen L, Ordulu Z, Dagogo-Jack I, Bossuyt V, Winters L, Taghian A, Smith BL, Ellisen LW, Kiedrowski LA, Lennerz JK, Bardia A, Spring LM. Locally Recurrent Secretory Carcinoma of the Breast with NTRK3 Gene Fusion. Oncologist. 2021 10; 26(10):818-824. PMID: 34176200.
    Citations: 1     Fields:    Translation:Humans
  11. Koh SB, Ross K, Isakoff SJ, Melkonjan N, He L, Matissek KJ, Schultz A, Mayer EL, Traina TA, Carey LA, Rugo HS, Liu MC, Stearns V, Langenbucher A, Saladi SV, Ramaswamy S, Lawrence MS, Ellisen LW. RASAL2 Confers Collateral MEK/EGFR Dependency in Chemoresistant Triple-Negative Breast Cancer. Clin Cancer Res. 2021 09 01; 27(17):4883-4897. PMID: 34168046; PMCID: PMC8416935.
    Citations: 4     Fields:    Translation:HumansCells
  12. Wander SA, Han HS, Zangardi ML, Niemierko A, Mariotti V, Kim LSL, Xi J, Pandey A, Dunne S, Nasrazadani A, Kambadakone A, Stein C, Lloyd MR, Yuen M, Spring LM, Juric D, Kuter I, Sanidas I, Moy B, Mulvey T, Vidula N, Dyson NJ, Ellisen LW, Isakoff S, Wagle N, Brufsky A, Kalinsky K, Ma CX, O'Shaughnessy J, Bardia A. Clinical Outcomes With Abemaciclib After Prior CDK4/6 Inhibitor Progression in Breast Cancer: A Multicenter Experience. J Natl Compr Canc Netw. 2021 Mar 24; 1-8. PMID: 33761455.
    Citations: 5     Fields:    
  13. Choi JE, Sebastian C, Ferrer CM, Lewis CA, Sade-Feldman M, LaSalle T, Gonye A, Lopez BGC, Abdelmoula WM, Regan MS, Cetinbas M, Pascual G, Wojtkiewicz GR, Silveira GG, Boon R, Ross KN, Tirosh I, Saladi SV, Ellisen LW, Sadreyev RI, Benitah SA, Agar NYR, Hacohen N, Mostoslavsky R. A unique subset of glycolytic tumour-propagating cells drives squamous cell carcinoma. Nat Metab. 2021 02; 3(2):182-195. PMID: 33619381; PMCID: PMC7954080.
    Citations: 3     Fields:    Translation:HumansAnimalsCells
  14. Vidula N, Niemierko A, Malvarosa G, Yuen M, Lennerz J, Iafrate AJ, Wander SA, Spring L, Juric D, Isakoff S, Younger J, Moy B, Ellisen LW, Bardia A. Tumor Tissue- versus Plasma-based Genotyping for Selection of Matched Therapy and Impact on Clinical Outcomes in Patients with Metastatic Breast Cancer. Clin Cancer Res. 2021 06 15; 27(12):3404-3413. PMID: 33504549.
    Citations: 2     Fields:    Translation:Humans
  15. Vidula N, Ellisen LW, Bardia A. Clinical application of liquid biopsies to detect somatic BRCA1/2 mutations and guide potential therapeutic intervention for patients with metastatic breast cancer. Oncotarget. 2021 Jan 19; 12(2):63-65. PMID: 33520111.
    Citations:    Fields:    
  16. Wang H, Wan X, Pilch PF, Ellisen LW, Fried SK, Liu L. An AMPK-dependent, non-canonical p53 pathway plays a key role in adipocyte metabolic reprogramming. Elife. 2020 12 15; 9. PMID: 33320092.
    Citations:    Fields:    Translation:AnimalsCells
  17. Beyerlin K, Jimenez R, Zangardi M, Fell GG, Edmonds C, Johnson A, Bossuyt V, Specht M, Mulvey TM, Moy B, Ellisen LW, Isakoff SJ, Bardia A, Spring LM. The adjuvant use of capecitabine for residual disease following pre-operative chemotherapy for breast cancer: Challenges applying CREATE-X to a US population. J Oncol Pharm Pract. 2021 Dec; 27(8):1883-1890. PMID: 33153384.
    Citations:    Fields:    Translation:Humans
  18. Velimirovic M, Juric D, Niemierko A, Spring L, Vidula N, Wander SA, Medford A, Parikh A, Malvarosa G, Yuen M, Corcoran R, Moy B, Isakoff SJ, Ellisen LW, Iafrate A, Chabner B, Bardia A. Rising Circulating Tumor DNA As a Molecular Biomarker of Early Disease Progression in Metastatic Breast Cancer. JCO Precis Oncol. 2020 Nov; 4:1246-1262. PMID: 35050782.
    Citations: 3     Fields:    
  19. Vidula N, Ellisen LW, Bardia A. Novel Agents for Metastatic Triple-Negative Breast Cancer: Finding the Positive in the Negative. J Natl Compr Canc Netw. 2020 10 15; 1-9. PMID: 33075745.
    Citations: 3     Fields:    
  20. Guhan SM, Artomov M, McCormick S, Njauw C-, Stratigos AJ, Shannon K, Ellisen LW, Tsao H. Cancer risks associated with the germline MITF(E318K) variant. Sci Rep. 2020 10 13; 10(1):17051. PMID: 33051548.
    Citations: 3     Fields:    Translation:HumansCells
  21. Vidula N, Dubash T, Lawrence MS, Simoneau A, Niemierko A, Blouch E, Nagy B, Roh W, Chirn B, Reeves BA, Malvarosa G, Lennerz J, Isakoff SJ, Juric D, Micalizzi D, Wander S, Spring L, Moy B, Shannon K, Younger J, Lanman R, Toner M, Iafrate AJ, Getz G, Zou L, Ellisen LW, Maheswaran S, Haber DA, Bardia A. Identification of Somatically Acquired BRCA1/2 Mutations by cfDNA Analysis in Patients with Metastatic Breast Cancer. Clin Cancer Res. 2020 09 15; 26(18):4852-4862. PMID: 32571788.
    Citations: 4     Fields:    Translation:HumansCells
  22. Nagayama A, Vidula N, Ellisen L, Bardia A. Novel antibody-drug conjugates for triple negative breast cancer. Ther Adv Med Oncol. 2020; 12:1758835920915980. PMID: 32426047; PMCID: PMC7222243.
    Citations: 23     
  23. Qiao S, Koh SB, Vivekanandan V, Salunke D, Patra KC, Zaganjor E, Ross K, Mizukami Y, Jeanfavre S, Chen A, Mino-Kenudson M, Ramaswamy S, Clish C, Haigis M, Bardeesy N, Ellisen LW. REDD1 loss reprograms lipid metabolism to drive progression of RAS mutant tumors. Genes Dev. 2020 06 01; 34(11-12):751-766. PMID: 32273287.
    Citations: 11     Fields:    Translation:HumansAnimalsCells
  24. Millar DG, Ramjiawan RR, Kawaguchi K, Gupta N, Chen J, Zhang S, Nojiri T, Ho WW, Aoki S, Jung K, Chen I, Shi F, Heather JM, Shigeta K, Morton LT, Sepulveda S, Wan L, Joseph R, Minogue E, Khatri A, Bardia A, Ellisen LW, Corcoran RB, Hata AN, Pai SI, Jain RK, Fukumura D, Duda DG, Cobbold M. Antibody-mediated delivery of viral epitopes to tumors harnesses CMV-specific T cells for cancer therapy. Nat Biotechnol. 2020 04; 38(4):420-425. PMID: 32042168.
    Citations: 19     Fields:    Translation:HumansAnimalsCells
  25. Karaayvaz-Yildirim M, Silberman RE, Langenbucher A, Saladi SV, Ross KN, Zarcaro E, Desmond A, Yildirim M, Vivekanandan V, Ravichandran H, Mylavagnanam R, Specht MC, Ramaswamy S, Lawrence M, Amon A, Ellisen LW. Aneuploidy and a deregulated DNA damage response suggest haploinsufficiency in breast tissues of BRCA2 mutation carriers. Sci Adv. 2020 01; 6(5):eaay2611. PMID: 32064343.
    Citations: 9     Fields:    Translation:HumansCells
  26. Costa C, Wang Y, Ly A, Hosono Y, Murchie E, Walmsley CS, Huynh T, Healy C, Peterson R, Yanase S, Jakubik CT, Henderson LE, Damon LJ, Timonina D, Sanidas I, Pinto CJ, Mino-Kenudson M, Stone JR, Dyson NJ, Ellisen LW, Bardia A, Ebi H, Benes CH, Engelman JA, Juric D. PTEN Loss Mediates Clinical Cross-Resistance to CDK4/6 and PI3Ka Inhibitors in Breast Cancer. Cancer Discov. 2020 01; 10(1):72-85. PMID: 31594766.
    Citations: 60     Fields:    Translation:HumansAnimalsCells
  27. Drago JZ, Formisano L, Juric D, Niemierko A, Servetto A, Wander SA, Spring LM, Vidula N, Younger J, Peppercorn J, Yuen M, Malvarosa G, Sgroi D, Isakoff SJ, Moy B, Ellisen LW, Iafrate AJ, Arteaga CL, Bardia A. FGFR1 Amplification Mediates Endocrine Resistance but Retains TORC Sensitivity in Metastatic Hormone Receptor-Positive (HR+) Breast Cancer. Clin Cancer Res. 2019 11 01; 25(21):6443-6451. PMID: 31371343; PMCID: PMC6825550.
    Citations: 22     Fields:    Translation:Humans
  28. Medford AJ, Dubash TD, Juric D, Spring L, Niemierko A, Vidula N, Peppercorn J, Isakoff S, Reeves BA, LiCausi JA, Wesley B, Malvarosa G, Yuen M, Wittner BS, Lawrence MS, Iafrate AJ, Ellisen L, Moy B, Toner M, Maheswaran S, Haber DA, Bardia A. Blood-based monitoring identifies acquired and targetable driver HER2 mutations in endocrine-resistant metastatic breast cancer. NPJ Precis Oncol. 2019; 3:18. PMID: 31341951; PMCID: PMC6635494.
    Citations: 10     
  29. Duchamp M, Liu T, van Genderen AM, Kappings V, Oklu R, Ellisen LW, Zhang YS. Sacrificial Bioprinting of a Mammary Ductal Carcinoma Model. Biotechnol J. 2019 Oct; 14(10):e1700703. PMID: 30963705.
    Citations: 7     Fields:    Translation:HumansCells
  30. Tanaka S, Batchelor TT, Iafrate AJ, Dias-Santagata D, Borger DR, Ellisen LW, Yang D, Louis DN, Cahill DP, Chi AS. PIK3CA activating mutations are associated with more disseminated disease at presentation and earlier recurrence in glioblastoma. Acta Neuropathol Commun. 2019 04 29; 7(1):66. PMID: 31036078; PMCID: PMC6487518.
    Citations: 14     Fields:    Translation:HumansCells
  31. Artomov M, Joseph V, Tiao G, Thomas T, Schrader K, Klein RJ, Kiezun A, Gupta N, Margolin L, Stratigos AJ, Kim I, Shannon K, Ellisen LW, Haber D, Getz G, Tsao H, Lipkin SM, Altshuler D, Offit K, Daly MJ. Case-control analysis identifies shared properties of rare germline variation in cancer predisposing genes. Eur J Hum Genet. 2019 05; 27(5):824-828. PMID: 30718883.
    Citations: 3     Fields:    Translation:Humans
  32. Karaayvaz M, Cristea S, Gillespie SM, Patel AP, Mylvaganam R, Luo CC, Specht MC, Bernstein BE, Michor F, Ellisen LW. Unravelling subclonal heterogeneity and aggressive disease states in TNBC through single-cell RNA-seq. Nat Commun. 2018 09 04; 9(1):3588. PMID: 30181541; PMCID: PMC6123496.
    Citations: 148     Fields:    Translation:HumansCells
  33. Tata PR, Chow RD, Saladi SV, Tata A, Konkimalla A, Bara A, Montoro D, Hariri LP, Shih AR, Mino-Kenudson M, Mou H, Kimura S, Ellisen LW, Rajagopal J. Developmental History Provides a Roadmap for the Emergence of Tumor Plasticity. Dev Cell. 2018 03 26; 44(6):679-693.e5. PMID: 29587142; PMCID: PMC5875457.
    Citations: 33     Fields:    Translation:HumansAnimalsCells
  34. Dizon DS, Dias-Santagata D, Bregar A, Sullivan L, Filipi J, DiTavi E, Miller L, Ellisen L, Birrer M, DelCarmen M. Complete Remission Following Pembrolizumab in a Woman with Mismatch Repair-Deficient Endometrial Cancer and a Germline BRCA1 Mutation. Oncologist. 2018 06; 23(6):650-653. PMID: 29472312.
    Citations: 3     Fields:    Translation:HumansCells
  35. Ellisen LW. Cognitive Computing to Guide Molecular-Based Therapy Selection: Steps Forward amid Abundant Need. Oncologist. 2018 02; 23(2):145-146. PMID: 29330209.
    Citations:    Fields:    Translation:Humans
  36. Matissek KJ, Onozato ML, Sun S, Zheng Z, Schultz A, Lee J, Patel K, Jerevall PL, Saladi SV, Macleay A, Tavallai M, Badovinac-Crnjevic T, Barrios C, Bese N, Chan A, Chavarri-Guerra Y, Debiasi M, Demirdögen E, Egeli Ü, Gökgöz S, Gomez H, Liedke P, Tasdelen I, Tolunay S, Werutsky G, St Louis J, Horick N, Finkelstein DM, Le LP, Bardia A, Goss PE, Sgroi DC, Iafrate AJ, Ellisen LW. Expressed Gene Fusions as Frequent Drivers of Poor Outcomes in Hormone Receptor-Positive Breast Cancer. Cancer Discov. 2018 03; 8(3):336-353. PMID: 29242214.
    Citations: 17     Fields:    Translation:HumansAnimalsCells
  37. Nagayama A, Ellisen LW, Chabner B, Bardia A. Antibody-Drug Conjugates for the Treatment of Solid Tumors: Clinical Experience and Latest Developments. Target Oncol. 2017 Dec; 12(6):719-739. PMID: 29116596.
    Citations: 18     Fields:    Translation:Humans
  38. Spring L, Greenup R, Niemierko A, Schapira L, Haddad S, Jimenez R, Coopey S, Taghian A, Hughes KS, Isakoff SJ, Ellisen LW, Smith BL, Specht M, Moy B, Bardia A. Pathologic Complete Response After Neoadjuvant Chemotherapy and Long-Term Outcomes Among Young Women With Breast Cancer. J Natl Compr Canc Netw. 2017 10; 15(10):1216-1223. PMID: 28982747.
    Citations: 31     Fields:    Translation:Humans
  39. Ellisen LW. A wound-healing program is hijacked to promote cancer metastasis. J Exp Med. 2017 Oct 02; 214(10):2813-2815. PMID: 28904109.
    Citations: 2     Fields:    Translation:Humans
  40. Gordon BS, Steiner JL, Rossetti ML, Qiao S, Ellisen LW, Govindarajan SS, Eroshkin AM, Williamson DL, Coen PM. REDD1 induction regulates the skeletal muscle gene expression signature following acute aerobic exercise. Am J Physiol Endocrinol Metab. 2017 12 01; 313(6):E737-E747. PMID: 28899858.
    Citations: 9     Fields:    Translation:AnimalsCells
  41. Polak P, Kim J, Braunstein LZ, Karlic R, Haradhavala NJ, Tiao G, Rosebrock D, Livitz D, Kübler K, Mouw KW, Kamburov A, Maruvka YE, Leshchiner I, Lander ES, Golub TR, Zick A, Orthwein A, Lawrence MS, Batra RN, Caldas C, Haber DA, Laird PW, Shen H, Ellisen LW, D'Andrea AD, Chanock SJ, Foulkes WD, Getz G. A mutational signature reveals alterations underlying deficient homologous recombination repair in breast cancer. Nat Genet. 2017 Oct; 49(10):1476-1486. PMID: 28825726; PMCID: PMC7376751.
    Citations: 203     Fields:    Translation:HumansCells
  42. Rheinbay E, Parasuraman P, Grimsby J, Tiao G, Engreitz JM, Kim J, Lawrence MS, Taylor-Weiner A, Rodriguez-Cuevas S, Rosenberg M, Hess J, Stewart C, Maruvka YE, Stojanov P, Cortes ML, Seepo S, Cibulskis C, Tracy A, Pugh TJ, Lee J, Zheng Z, Ellisen LW, Iafrate AJ, Boehm JS, Gabriel SB, Meyerson M, Golub TR, Baselga J, Hidalgo-Miranda A, Shioda T, Bernards A, Lander ES, Getz G. Recurrent and functional regulatory mutations in breast cancer. Nature. 2017 07 06; 547(7661):55-60. PMID: 28658208.
    Citations: 123     Fields:    Translation:HumansCells
  43. Saladi SV, Ross K, Karaayvaz M, Tata PR, Mou H, Rajagopal J, Ramaswamy S, Ellisen LW. ACTL6A Is Co-Amplified with p63 in Squamous Cell Carcinoma to Drive YAP Activation, Regenerative Proliferation, and Poor Prognosis. Cancer Cell. 2017 01 09; 31(1):35-49. PMID: 28041841; PMCID: PMC5225026.
    Citations: 86     Fields:    Translation:HumansAnimalsCells
  44. Spring LM, Gupta A, Reynolds KL, Gadd MA, Ellisen LW, Isakoff SJ, Moy B, Bardia A. Neoadjuvant Endocrine Therapy for Estrogen Receptor-Positive Breast Cancer: A Systematic Review and Meta-analysis. JAMA Oncol. 2016 Nov 01; 2(11):1477-1486. PMID: 27367583; PMCID: PMC5738656.
    Citations: 94     Fields:    Translation:Humans
  45. Zhang YS, Duchamp M, Oklu R, Ellisen LW, Langer R, Khademhosseini A. Bioprinting the Cancer Microenvironment. ACS Biomater Sci Eng. 2016 Oct 10; 2(10):1710-1721. PMID: 28251176; PMCID: PMC5328669.
    Citations: 70     Fields:    
  46. Rodriguez Calleja L, Jacques C, Lamoureux F, Baud'huin M, Tellez Gabriel M, Quillard T, Sahay D, Perrot P, Amiaud J, Charrier C, Brion R, Lecanda F, Verrecchia F, Heymann D, Ellisen LW, Ory B. ?Np63a Silences a miRNA Program to Aberrantly Initiate a Wound-Healing Program That Promotes TGFß-Induced Metastasis. Cancer Res. 2016 06 01; 76(11):3236-51. PMID: 26988989; PMCID: PMC4891241.
    Citations: 30     Fields:    Translation:HumansAnimalsCells
  47. Sabatini ME, Ellisen LW. Women's Health Issues for BRCA Mutation Carriers. Am Soc Clin Oncol Educ Book. 2016; 35:14-7. PMID: 27249681.
    Citations: 1     Fields:    Translation:Humans
  48. Desmond A, Kurian AW, Gabree M, Mills MA, Anderson MJ, Kobayashi Y, Horick N, Yang S, Shannon KM, Tung N, Ford JM, Lincoln SE, Ellisen LW. Clinical Actionability of Multigene Panel Testing for Hereditary Breast and Ovarian Cancer Risk Assessment. JAMA Oncol. 2015 Oct; 1(7):943-51. PMID: 26270727.
    Citations: 132     Fields:    Translation:Humans
  49. Keenan T, Moy B, Mroz EA, Ross K, Niemierko A, Rocco JW, Isakoff S, Ellisen LW, Bardia A. Comparison of the Genomic Landscape Between Primary Breast Cancer in African American Versus White Women and the Association of Racial Differences With Tumor Recurrence. J Clin Oncol. 2015 Nov 01; 33(31):3621-7. PMID: 26371147; PMCID: PMC4979243.
    Citations: 90     Fields:    Translation:Humans
  50. Lincoln SE, Kobayashi Y, Anderson MJ, Yang S, Desmond AJ, Mills MA, Nilsen GB, Jacobs KB, Monzon FA, Kurian AW, Ford JM, Ellisen LW. A Systematic Comparison of Traditional and Multigene Panel Testing for Hereditary Breast and Ovarian Cancer Genes in More Than 1000 Patients. J Mol Diagn. 2015 Sep; 17(5):533-44. PMID: 26207792.
    Citations: 78     Fields:    Translation:Humans
  51. Qiao S, Dennis M, Song X, Vadysirisack DD, Salunke D, Nash Z, Yang Z, Liesa M, Yoshioka J, Matsuzawa S, Shirihai OS, Lee RT, Reed JC, Ellisen LW. A REDD1/TXNIP pro-oxidant complex regulates ATG4B activity to control stress-induced autophagy and sustain exercise capacity. Nat Commun. 2015 Apr 28; 6:7014. PMID: 25916556.
    Citations: 75     Fields:    Translation:AnimalsCells
  52. Isakoff SJ, Mayer EL, He L, Traina TA, Carey LA, Krag KJ, Rugo HS, Liu MC, Stearns V, Come SE, Timms KM, Hartman AR, Borger DR, Finkelstein DM, Garber JE, Ryan PD, Winer EP, Goss PE, Ellisen LW. TBCRC009: A Multicenter Phase II Clinical Trial of Platinum Monotherapy With Biomarker Assessment in Metastatic Triple-Negative Breast Cancer. J Clin Oncol. 2015 Jun 10; 33(17):1902-9. PMID: 25847936; PMCID: PMC4451173.
    Citations: 147     Fields:    Translation:HumansCTClinical Trials
  53. Tung N, Battelli C, Allen B, Kaldate R, Bhatnagar S, Bowles K, Timms K, Garber JE, Herold C, Ellisen L, Krejdovsky J, DeLeonardis K, Sedgwick K, Soltis K, Roa B, Wenstrup RJ, Hartman AR. Frequency of mutations in individuals with breast cancer referred for BRCA1 and BRCA2 testing using next-generation sequencing with a 25-gene panel. Cancer. 2015 Jan 01; 121(1):25-33. PMID: 25186627.
    Citations: 159     Fields:    Translation:Humans
  54. Zhao R, Fallon TR, Saladi SV, Pardo-Saganta A, Villoria J, Mou H, Vinarsky V, Gonzalez-Celeiro M, Nunna N, Hariri LP, Camargo F, Ellisen LW, Rajagopal J. Yap tunes airway epithelial size and architecture by regulating the identity, maintenance, and self-renewal of stem cells. Dev Cell. 2014 Jul 28; 30(2):151-65. PMID: 25043474; PMCID: PMC4130488.
    Citations: 94     Fields:    Translation:AnimalsCells
  55. Wakimoto H, Tanaka S, Curry WT, Loebel F, Zhao D, Tateishi K, Chen J, Klofas LK, Lelic N, Kim JC, Dias-Santagata D, Ellisen LW, Borger DR, Fendt SM, Vander Heiden MG, Batchelor TT, Iafrate AJ, Cahill DP, Chi AS. Targetable signaling pathway mutations are associated with malignant phenotype in IDH-mutant gliomas. Clin Cancer Res. 2014 Jun 01; 20(11):2898-909. PMID: 24714777.
    Citations: 69     Fields:    Translation:HumansAnimals
  56. Dienstmann R, Dong F, Borger D, Dias-Santagata D, Ellisen LW, Le LP, Iafrate AJ. Standardized decision support in next generation sequencing reports of somatic cancer variants. Mol Oncol. 2014 Jul; 8(5):859-73. PMID: 24768039.
    Citations: 43     Fields:    Translation:Humans
  57. McBride SM, Rothenberg SM, Faquin WC, Chan AW, Clark JR, Ellisen LW, Wirth LJ. Mutation frequency in 15 common cancer genes in high-risk head and neck squamous cell carcinoma. Head Neck. 2014 Aug; 36(8):1181-8. PMID: 23852799.
    Citations: 12     Fields:    Translation:Humans
  58. Russo AL, Borger DR, Szymonifka J, Ryan DP, Wo JY, Blaszkowsky LS, Kwak EL, Allen JN, Wadlow RC, Zhu AX, Murphy JE, Faris JE, Dias-Santagata D, Haigis KM, Ellisen LW, Iafrate AJ, Hong TS. Mutational analysis and clinical correlation of metastatic colorectal cancer. Cancer. 2014 May 15; 120(10):1482-90. PMID: 24500602; PMCID: PMC4327902.
    Citations: 33     Fields:    Translation:Humans
  59. Borger DR, Goyal L, Yau T, Poon RT, Ancukiewicz M, Deshpande V, Christiani DC, Liebman HM, Yang H, Kim H, Yen K, Faris JE, Iafrate AJ, Kwak EL, Clark JW, Allen JN, Blaszkowsky LS, Murphy JE, Saha SK, Hong TS, Wo JY, Ferrone CR, Tanabe KK, Bardeesy N, Straley KS, Agresta S, Schenkein DP, Ellisen LW, Ryan DP, Zhu AX. Circulating oncometabolite 2-hydroxyglutarate is a potential surrogate biomarker in patients with isocitrate dehydrogenase-mutant intrahepatic cholangiocarcinoma. Clin Cancer Res. 2014 Apr 01; 20(7):1884-90. PMID: 24478380; PMCID: PMC4107454.
    Citations: 52     Fields:    Translation:Humans
  60. Forster N, Saladi SV, van Bragt M, Sfondouris ME, Jones FE, Li Z, Ellisen LW. Basal cell signaling by p63 controls luminal progenitor function and lactation via NRG1. Dev Cell. 2014 Jan 27; 28(2):147-60. PMID: 24412575.
    Citations: 59     Fields:    Translation:HumansAnimalsCells
  61. Akhavanfard S, Vargas SO, Han M, Nitta M, Chang CB, Le LP, Fazlollahi L, Nguyen Q, Ma Y, Cosper A, Dias-Santagata D, Han JY, Bergethon K, Borger DR, Ellisen LW, Pomeroy SL, Haber DA, Iafrate AJ, Rivera MN. Inactivation of the tumor suppressor WTX in a subset of pediatric tumors. Genes Chromosomes Cancer. 2014 Jan; 53(1):67-77. PMID: 24249259.
    Citations: 3     Fields:    Translation:Humans
  62. Juric D, Isakoff SJ, Borger DR, Dias-Santagata D, Higgins MJ, Iafrate AJ, Flaherty K, Moy B, Ellisen LW. Impact of routine tumor genotyping on enrollment in targeted therapy trials for metastatic breast cancer (MBC): 4-year review. J Clin Oncol. 2013 Sep 10; 31(26_suppl):145. PMID: 28136532.
  63. Ramsey MR, Wilson C, Ory B, Rothenberg SM, Faquin W, Mills AA, Ellisen LW. FGFR2 signaling underlies p63 oncogenic function in squamous cell carcinoma. J Clin Invest. 2013 Aug; 123(8):3525-38. PMID: 23867503; PMCID: PMC3726171.
    Citations: 56     Fields:    Translation:HumansAnimalsCells
  64. Chabner BA, Ellisen LW, Iafrate AJ. Personalized medicine: hype or reality. Oncologist. 2013 Jun; 18(6):640-3. PMID: 23814157.
    Citations: 6     Fields:    Translation:Humans
  65. Chi AS, Batchelor TT, Yang D, Dias-Santagata D, Borger DR, Ellisen LW, Iafrate AJ, Louis DN. BRAF V600E mutation identifies a subset of low-grade diffusely infiltrating gliomas in adults. J Clin Oncol. 2013 May 10; 31(14):e233-6. PMID: 23547069.
    Citations: 25     Fields:    Translation:Humans
  66. Patenaude AF, Tung N, Ryan PD, Ellisen LW, Hewitt L, Schneider KA, Tercyak KP, Aldridge J, Garber JE. Young adult daughters of BRCA1/2 positive mothers: what do they know about hereditary cancer and how much do they worry? Psychooncology. 2013 Sep; 22(9):2024-31. PMID: 23417902.
    Citations: 20     Fields:    Translation:Humans
  67. He L, Torres-Lockhart K, Forster N, Ramakrishnan S, Greninger P, Garnett MJ, McDermott U, Rothenberg SM, Benes CH, Ellisen LW. Mcl-1 and FBW7 control a dominant survival pathway underlying HDAC and Bcl-2 inhibitor synergy in squamous cell carcinoma. Cancer Discov. 2013 Mar; 3(3):324-37. PMID: 23274910.
    Citations: 33     Fields:    Translation:HumansAnimalsCells
  68. Gallant-Behm CL, Ramsey MR, Bensard CL, Nojek I, Tran J, Liu M, Ellisen LW, Espinosa JM. ?Np63a represses anti-proliferative genes via H2A.Z deposition. Genes Dev. 2012 Oct 15; 26(20):2325-36. PMID: 23019126.
    Citations: 33     Fields:    Translation:HumansCells
  69. Ibrahim YH, García-García C, Serra V, He L, Torres-Lockhart K, Prat A, Anton P, Cozar P, Guzmán M, Grueso J, Rodríguez O, Calvo MT, Aura C, Díez O, Rubio IT, Pérez J, Rodón J, Cortés J, Ellisen LW, Scaltriti M, Baselga J. PI3K inhibition impairs BRCA1/2 expression and sensitizes BRCA-proficient triple-negative breast cancer to PARP inhibition. Cancer Discov. 2012 Nov; 2(11):1036-47. PMID: 22915752.
    Citations: 254     Fields:    Translation:HumansCells
  70. Chi AS, Batchelor TT, Dias-Santagata D, Borger D, Stiles CD, Wang DL, Curry WT, Wen PY, Ligon KL, Ellisen L, Louis DN, Iafrate AJ. Prospective, high-throughput molecular profiling of human gliomas. J Neurooncol. 2012 Oct; 110(1):89-98. PMID: 22821383.
    Citations: 30     Fields:    Translation:Humans
  71. Rothenberg SM, Ellisen LW. The molecular pathogenesis of head and neck squamous cell carcinoma. J Clin Invest. 2012 Jun; 122(6):1951-7. PMID: 22833868; PMCID: PMC3589176.
    Citations: 169     Fields:    Translation:HumansCells
  72. Vadysirisack DD, Ellisen LW. mTOR activity under hypoxia. Methods Mol Biol. 2012; 821:45-58. PMID: 22125059; PMCID: PMC3960283.
    Citations: 20     Fields:    Translation:HumansAnimalsCells
  73. Borger DR, Tanabe KK, Fan KC, Lopez HU, Fantin VR, Straley KS, Schenkein DP, Hezel AF, Ancukiewicz M, Liebman HM, Kwak EL, Clark JW, Ryan DP, Deshpande V, Dias-Santagata D, Ellisen LW, Zhu AX, Iafrate AJ. Frequent mutation of isocitrate dehydrogenase (IDH)1 and IDH2 in cholangiocarcinoma identified through broad-based tumor genotyping. Oncologist. 2012; 17(1):72-9. PMID: 22180306; PMCID: PMC3267826.
    Citations: 300     Fields:    Translation:Humans
  74. Sequist LV, Heist RS, Shaw AT, Fidias P, Rosovsky R, Temel JS, Lennes IT, Digumarthy S, Waltman BA, Bast E, Tammireddy S, Morrissey L, Muzikansky A, Goldberg SB, Gainor J, Channick CL, Wain JC, Gaissert H, Donahue DM, Muniappan A, Wright C, Willers H, Mathisen DJ, Choi NC, Baselga J, Lynch TJ, Ellisen LW, Mino-Kenudson M, Lanuti M, Borger DR, Iafrate AJ, Engelman JA, Dias-Santagata D. Implementing multiplexed genotyping of non-small-cell lung cancers into routine clinical practice. Ann Oncol. 2011 Dec; 22(12):2616-2624. PMID: 22071650.
    Citations: 148     Fields:    Translation:Humans
  75. Forster N, Ellisen LW. Notch signaling mediates p63-induced quiescence: a new facet of p63/Notch crosstalk. Cell Cycle. 2011 Nov 01; 10(21):3632-3. PMID: 22041817.
    Citations: 4     Fields:    Translation:HumansAnimals
  76. Vadysirisack DD, Baenke F, Ory B, Lei K, Ellisen LW. Feedback control of p53 translation by REDD1 and mTORC1 limits the p53-dependent DNA damage response. Mol Cell Biol. 2011 Nov; 31(21):4356-65. PMID: 21896779; PMCID: PMC3209328.
    Citations: 22     Fields:    Translation:AnimalsCells
  77. Ramsey MR, Ellisen LW. Circadian function in cancer: regulating the DNA damage response. Proc Natl Acad Sci U S A. 2011 Jun 28; 108(26):10379-80. PMID: 21673139.
    Citations: 5     Fields:    Translation:Humans
  78. Wirth LJ, Nardi V, Juric D, Cosper AK, Bergethon K, Scialabba V, Borger DR, Iafrate AJ, Ellisen LW, Deschler D, Zhao D, Sadow PM, Dias-Santagata D. Detection of novel genetic aberrations in salivary duct carcinoma (SDC) by SNaPshot analysis. J Clin Oncol. 2011 May 20; 29(15_suppl):5579. PMID: 28022120.
  79. Isakoff SJ, Goss PE, Mayer EL, Traina TA, Carey LA, Krag K, Rugo HS, Liu MC, Stearns V, Come SE, Borger DR, Quadrino CA, Finkelstein D, Garber JE, Ryan PD, Winer EP, Ellisen LW. TBCRC009: A multicenter phase II study of cisplatin or carboplatin for metastatic triple-negative breast cancer and evaluation of p63/p73 as a biomarker of response. J Clin Oncol. 2011 May 20; 29(15_suppl):1025. PMID: 28020734.
  80. Ramsey MR, He L, Forster N, Ory B, Ellisen LW. Physical association of HDAC1 and HDAC2 with p63 mediates transcriptional repression and tumor maintenance in squamous cell carcinoma. Cancer Res. 2011 Jul 01; 71(13):4373-9. PMID: 21527555.
    Citations: 61     Fields:    Translation:HumansAnimalsCells
  81. Ory B, Ellisen LW. A microRNA-dependent circuit controlling p63/p73 homeostasis: p53 family cross-talk meets therapeutic opportunity. Oncotarget. 2011 Mar; 2(3):259-64. PMID: 21436470.
    Citations: 37     Fields:    Translation:HumansAnimals
  82. Ellisen LW. PARP inhibitors in cancer therapy: promise, progress, and puzzles. Cancer Cell. 2011 Feb 15; 19(2):165-7. PMID: 21316599.
    Citations: 26     Fields:    
  83. Ory B, Ramsey MR, Wilson C, Vadysirisack DD, Forster N, Rocco JW, Rothenberg SM, Ellisen LW. A microRNA-dependent program controls p53-independent survival and chemosensitivity in human and murine squamous cell carcinoma. J Clin Invest. 2011 Feb; 121(2):809-20. PMID: 21293058; PMCID: PMC3026726.
    Citations: 44     Fields:    Translation:HumansAnimalsCells
  84. Growdon WB, Roussel BN, Scialabba VL, Foster R, Dias-Santagata D, Iafrate AJ, Ellisen LW, Tambouret RH, Rueda BR, Borger DR. Tissue-specific signatures of activating PIK3CA and RAS mutations in carcinosarcomas of gynecologic origin. Gynecol Oncol. 2011 Apr; 121(1):212-7. PMID: 21168197.
    Citations: 13     Fields:    Translation:Humans
  85. Yang C, Hayashida T, Forster N, Li C, Shen D, Maheswaran S, Chen L, Anderson KS, Ellisen LW, Sgroi D, Schmidt EV. The integrin alpha(v)beta(3-5) ligand MFG-E8 is a p63/p73 target gene in triple-negative breast cancers but exhibits suppressive functions in ER(+) and erbB2(+) breast cancers. Cancer Res. 2011 Feb 01; 71(3):937-45. PMID: 21127199.
    Citations: 31     Fields:    Translation:HumansAnimalsCells
  86. Ibrahim N, He L, Leong CO, Xing D, Karlan BY, Swisher EM, Rueda BR, Orsulic S, Ellisen LW. BRCA1-associated epigenetic regulation of p73 mediates an effector pathway for chemosensitivity in ovarian carcinoma. Cancer Res. 2010 Sep 15; 70(18):7155-65. PMID: 20807817.
    Citations: 26     Fields:    Translation:HumansAnimalsCells
  87. Ellisen LW. Smoking and emphysema: the stress connection. Nat Med. 2010 Jul; 16(7):754-5. PMID: 20613751.
    Citations: 5     Fields:    Translation:HumansAnimals
  88. Dias-Santagata D, Akhavanfard S, David SS, Vernovsky K, Kuhlmann G, Boisvert SL, Stubbs H, McDermott U, Settleman J, Kwak EL, Clark JW, Isakoff SJ, Sequist LV, Engelman JA, Lynch TJ, Haber DA, Louis DN, Ellisen LW, Borger DR, Iafrate AJ. Rapid targeted mutational analysis of human tumours: a clinical platform to guide personalized cancer medicine. EMBO Mol Med. 2010 May; 2(5):146-58. PMID: 20432502.
    Citations: 198     Fields:    Translation:Humans
  89. Horak P, Crawford AR, Vadysirisack DD, Nash ZM, DeYoung MP, Sgroi D, Ellisen LW. Negative feedback control of HIF-1 through REDD1-regulated ROS suppresses tumorigenesis. Proc Natl Acad Sci U S A. 2010 Mar 09; 107(10):4675-80. PMID: 20176937.
    Citations: 89     Fields:    Translation:HumansAnimalsCells
  90. Silver DP, Richardson AL, Eklund AC, Wang ZC, Szallasi Z, Li Q, Juul N, Leong CO, Calogrias D, Buraimoh A, Fatima A, Gelman RS, Ryan PD, Tung NM, De Nicolo A, Ganesan S, Miron A, Colin C, Sgroi DC, Ellisen LW, Winer EP, Garber JE. Efficacy of neoadjuvant Cisplatin in triple-negative breast cancer. J Clin Oncol. 2010 Mar 01; 28(7):1145-53. PMID: 20100965.
    Citations: 388     Fields:    Translation:HumansCells
  91. Zhong L, D'Urso A, Toiber D, Sebastian C, Henry RE, Vadysirisack DD, Guimaraes A, Marinelli B, Wikstrom JD, Nir T, Clish CB, Vaitheesvaran B, Iliopoulos O, Kurland I, Dor Y, Weissleder R, Shirihai OS, Ellisen LW, Espinosa JM, Mostoslavsky R. The histone deacetylase Sirt6 regulates glucose homeostasis via Hif1alpha. Cell. 2010 Jan 22; 140(2):280-93. PMID: 20141841; PMCID: PMC2821045.
    Citations: 465     Fields:    Translation:AnimalsCells
  92. Lim LY, Vidnovic N, Ellisen LW, Leong CO. Mutant p53 mediates survival of breast cancer cells. Br J Cancer. 2009 Nov 03; 101(9):1606-12. PMID: 19773755.
    Citations: 79     Fields:    Translation:HumansCells
  93. Michaud WA, Nichols AC, Mroz EA, Faquin WC, Clark JR, Begum S, Westra WH, Wada H, Busse PM, Ellisen LW, Rocco JW. Bcl-2 blocks cisplatin-induced apoptosis and predicts poor outcome following chemoradiation treatment in advanced oropharyngeal squamous cell carcinoma. Clin Cancer Res. 2009 Mar 01; 15(5):1645-54. PMID: 19240170.
    Citations: 37     Fields:    Translation:HumansCells
  94. Harvey KF, Mattila J, Sofer A, Bennett FC, Ramsey MR, Ellisen LW, Puig O, Hariharan IK. FOXO-regulated transcription restricts overgrowth of Tsc mutant organs. J Cell Biol. 2008 Feb 25; 180(4):691-6. PMID: 18299344; PMCID: PMC2265581.
    Citations: 23     Fields:    Translation:AnimalsCells
  95. Li N, Singh S, Cherukuri P, Li H, Yuan Z, Ellisen LW, Wang B, Robbins D, DiRenzo J. Reciprocal intraepithelial interactions between TP63 and hedgehog signaling regulate quiescence and activation of progenitor elaboration by mammary stem cells. Stem Cells. 2008 May; 26(5):1253-64. PMID: 18292212.
    Citations: 49     Fields:    Translation:HumansAnimalsCells
  96. DeYoung MP, Horak P, Sofer A, Sgroi D, Ellisen LW. Hypoxia regulates TSC1/2-mTOR signaling and tumor suppression through REDD1-mediated 14-3-3 shuttling. Genes Dev. 2008 Jan 15; 22(2):239-51. PMID: 18198340; PMCID: PMC2192757.
    Citations: 335     Fields:    Translation:HumansAnimalsCells
  97. Leong CO, Vidnovic N, DeYoung MP, Sgroi D, Ellisen LW. The p63/p73 network mediates chemosensitivity to cisplatin in a biologically defined subset of primary breast cancers. J Clin Invest. 2007 May; 117(5):1370-80. PMID: 17446929; PMCID: PMC1849987.
    Citations: 122     Fields:    Translation:HumansCells
  98. Deyoung MP, Ellisen LW. p63 and p73 in human cancer: defining the network. Oncogene. 2007 Aug 09; 26(36):5169-83. PMID: 17334395.
    Citations: 121     Fields:    Translation:HumansCells
  99. Wang H, Kubica N, Ellisen LW, Jefferson LS, Kimball SR. Dexamethasone represses signaling through the mammalian target of rapamycin in muscle cells by enhancing expression of REDD1. J Biol Chem. 2006 Dec 22; 281(51):39128-34. PMID: 17074751.
    Citations: 109     Fields:    Translation:AnimalsCells
  100. DeYoung MP, Johannessen CM, Leong CO, Faquin W, Rocco JW, Ellisen LW. Tumor-specific p73 up-regulation mediates p63 dependence in squamous cell carcinoma. Cancer Res. 2006 Oct 01; 66(19):9362-8. PMID: 17018588.
    Citations: 56     Fields:    Translation:HumansAnimalsCells
  101. Carroll DK, Carroll JS, Leong CO, Cheng F, Brown M, Mills AA, Brugge JS, Ellisen LW. p63 regulates an adhesion programme and cell survival in epithelial cells. Nat Cell Biol. 2006 Jun; 8(6):551-61. PMID: 16715076.
    Citations: 209     Fields:    Translation:HumansCells
  102. Rocco JW, Ellisen LW. p63 and p73: life and death in squamous cell carcinoma. Cell Cycle. 2006 May; 5(9):936-40. PMID: 16687923.
    Citations: 16     Fields:    Translation:HumansAnimalsCells
  103. Rocco JW, Leong CO, Kuperwasser N, DeYoung MP, Ellisen LW. p63 mediates survival in squamous cell carcinoma by suppression of p73-dependent apoptosis. Cancer Cell. 2006 Jan; 9(1):45-56. PMID: 16413471.
    Citations: 218     Fields:    Translation:HumansCells
  104. Ellisen LW. Growth control under stress: mTOR regulation through the REDD1-TSC pathway. Cell Cycle. 2005 Nov; 4(11):1500-02. PMID: 16258273.
    Citations: 54     Fields:    Translation:HumansAnimalsCells
  105. Sofer A, Lei K, Johannessen CM, Ellisen LW. Regulation of mTOR and cell growth in response to energy stress by REDD1. Mol Cell Biol. 2005 Jul; 25(14):5834-45. PMID: 15988001; PMCID: PMC1168803.
    Citations: 207     Fields:    Translation:HumansAnimalsCells
  106. Brugarolas J, Lei K, Hurley RL, Manning BD, Reiling JH, Hafen E, Witters LA, Ellisen LW, Kaelin WG. Regulation of mTOR function in response to hypoxia by REDD1 and the TSC1/TSC2 tumor suppressor complex. Genes Dev. 2004 Dec 01; 18(23):2893-904. PMID: 15545625; PMCID: PMC534650.
    Citations: 594     Fields:    Translation:AnimalsCells
  107. Burstein HJ, Harris LN, Gelman R, Lester SC, Nunes RA, Kaelin CM, Parker LM, Ellisen LW, Kuter I, Gadd MA, Christian RL, Kennedy PR, Borges VF, Bunnell CA, Younger J, Smith BL, Winer EP. Preoperative therapy with trastuzumab and paclitaxel followed by sequential adjuvant doxorubicin/cyclophosphamide for HER2 overexpressing stage II or III breast cancer: a pilot study. J Clin Oncol. 2003 Jan 01; 21(1):46-53. PMID: 12506169.
    Citations: 63     Fields:    Translation:HumansCTClinical Trials
  108. Ellisen LW, Ramsayer KD, Johannessen CM, Yang A, Beppu H, Minda K, Oliner JD, McKeon F, Haber DA. REDD1, a developmentally regulated transcriptional target of p63 and p53, links p63 to regulation of reactive oxygen species. Mol Cell. 2002 Nov; 10(5):995-1005. PMID: 12453409.
    Citations: 207     Fields:    Translation:HumansAnimalsCells
  109. Ellisen LW. Regulation of gene expression by WT1 in development and tumorigenesis. Int J Hematol. 2002 Aug; 76(2):110-6. PMID: 12215008.
    Citations: 7     Fields:    Translation:HumansAnimals
  110. Ellisen LW, Palmer RE, Maki RG, Truong VB, Tamayo P, Oliner JD, Haber DA. Cascades of transcriptional induction during human lymphocyte activation. Eur J Cell Biol. 2001 May; 80(5):321-8. PMID: 11432721.
    Citations: 12     Fields:    Translation:HumansCells
  111. Ellisen LW, Carlesso N, Cheng T, Scadden DT, Haber DA. The Wilms tumor suppressor WT1 directs stage-specific quiescence and differentiation of human hematopoietic progenitor cells. EMBO J. 2001 Apr 17; 20(8):1897-909. PMID: 11296223; PMCID: PMC125233.
    Citations: 40     Fields:    Translation:HumansCells
  112. Wang W, Lee SB, Palmer R, Ellisen LW, Haber DA. A functional interaction with CBP contributes to transcriptional activation by the Wilms tumor suppressor WT1. J Biol Chem. 2001 May 18; 276(20):16810-6. PMID: 11278547.
    Citations: 13     Fields:    Translation:AnimalsCells
  113. Harkin DP, Bean JM, Miklos D, Song YH, Truong VB, Englert C, Christians FC, Ellisen LW, Maheswaran S, Oliner JD, Haber DA. Induction of GADD45 and JNK/SAPK-dependent apoptosis following inducible expression of BRCA1. Cell. 1999 May 28; 97(5):575-86. PMID: 10367887.
    Citations: 137     Fields:    Translation:HumansCells
  114. Kolquist KA, Ellisen LW, Counter CM, Meyerson M, Tan LK, Weinberg RA, Haber DA, Gerald WL. Expression of TERT in early premalignant lesions and a subset of cells in normal tissues. Nat Genet. 1998 Jun; 19(2):182-6. PMID: 9620778.
    Citations: 91     Fields:    Translation:HumansCells
  115. Counter CM, Meyerson M, Eaton EN, Ellisen LW, Caddle SD, Haber DA, Weinberg RA. Telomerase activity is restored in human cells by ectopic expression of hTERT (hEST2), the catalytic subunit of telomerase. Oncogene. 1998 Mar 05; 16(9):1217-22. PMID: 9528864.
    Citations: 123     Fields:    Translation:HumansCells
  116. Ellisen LW, Haber DA. Hereditary breast cancer. Annu Rev Med. 1998; 49:425-36. PMID: 9509273.
    Citations: 20     Fields:    Translation:Humans
  117. Meyerson M, Counter CM, Eaton EN, Ellisen LW, Steiner P, Caddle SD, Ziaugra L, Beijersbergen RL, Davidoff MJ, Liu Q, Bacchetti S, Haber DA, Weinberg RA. hEST2, the putative human telomerase catalytic subunit gene, is up-regulated in tumor cells and during immortalization. Cell. 1997 Aug 22; 90(4):785-95. PMID: 9288757.
    Citations: 472     Fields:    Translation:HumansCells
  118. Ellisen LW, Bird J, West DC, Soreng AL, Reynolds TC, Smith SD, Sklar J. TAN-1, the human homolog of the Drosophila notch gene, is broken by chromosomal translocations in T lymphoblastic neoplasms. Cell. 1991 Aug 23; 66(4):649-61. PMID: 1831692.
    Citations: 523     Fields:    Translation:HumansAnimalsCells
  119. Weiss LM, Wood GS, Ellisen LW, Reynolds TC, Sklar J. Clonal T-cell populations in pityriasis lichenoides et varioliformis acuta (Mucha-Habermann disease). Am J Pathol. 1987 Mar; 126(3):417-21. PMID: 3030116; PMCID: PMC1899651.
    Citations: 15     Fields:    Translation:HumansCells
Local representatives can answer questions about the Profiles website or help with editing a profile or issues with profile data. For assistance with this profile: HMS/HSDM faculty should contact contactcatalyst.harvard.edu. For faculty or fellow appointment updates and changes, please ask your appointing department to contact HMS. For fellow personal and demographic information, contact HMS Human Resources at human_resourceshms.harvard.edu. For faculty personal and demographic information, contact HMS Office for Faculty Affairs at facappthms.harvard.edu.
Ellisen's Networks
Click the
buttons for more information and interactive visualizations!
Concepts (504)
Co-Authors (164)
Similar People (60)
Same Department 
Physical Neighbors
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.